Shares of Cardiovascular Systems, Inc. (NASDAQ:CSII) have been assigned an average rating of “Hold” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $34.40.
CSII has been the subject of several research analyst reports. BidaskClub raised shares of Cardiovascular Systems from a “hold” rating to a “buy” rating in a report on Friday, June 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $37.00 price objective (up previously from $32.00) on shares of Cardiovascular Systems in a report on Friday, July 14th. Zacks Investment Research downgraded shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Finally, Bank of America Corporation downgraded shares of Cardiovascular Systems from a “neutral” rating to an “underperform” rating in a report on Wednesday, June 21st.
Shares of Cardiovascular Systems (NASDAQ:CSII) opened at 31.40 on Friday. Cardiovascular Systems has a 52 week low of $21.29 and a 52 week high of $33.11. The company has a 50 day moving average of $30.79 and a 200 day moving average of $29.99. The firm’s market cap is $1.04 billion.
Cardiovascular Systems (NASDAQ:CSII) last posted its quarterly earnings data on Wednesday, August 2nd. The medical device company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.07. The business had revenue of $52.90 million during the quarter, compared to the consensus estimate of $51.98 million. Cardiovascular Systems had a negative net margin of 0.87% and a positive return on equity of 0.88%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.15) earnings per share. On average, equities research analysts anticipate that Cardiovascular Systems will post $0.01 EPS for the current fiscal year.
In other Cardiovascular Systems news, insider Laura Gillund sold 2,350 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $30.42, for a total value of $71,487.00. Following the completion of the sale, the insider now directly owns 88,633 shares of the company’s stock, valued at approximately $2,696,215.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Alexander Rosenstein sold 979 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $30.71, for a total transaction of $30,065.09. Following the completion of the sale, the general counsel now directly owns 52,296 shares of the company’s stock, valued at $1,606,010.16. The disclosure for this sale can be found here. Insiders sold a total of 51,065 shares of company stock valued at $1,514,031 over the last three months. 3.60% of the stock is owned by corporate insiders.
A number of large investors have recently modified their holdings of the stock. Quantbot Technologies LP increased its stake in shares of Cardiovascular Systems by 142.3% in the first quarter. Quantbot Technologies LP now owns 5,323 shares of the medical device company’s stock worth $150,000 after buying an additional 3,126 shares during the last quarter. Old Mutual Global Investors UK Ltd. acquired a new stake in shares of Cardiovascular Systems during the first quarter worth $163,000. BNP Paribas Arbitrage SA increased its stake in shares of Cardiovascular Systems by 160.7% in the second quarter. BNP Paribas Arbitrage SA now owns 5,135 shares of the medical device company’s stock worth $166,000 after buying an additional 3,165 shares during the last quarter. BlueCrest Capital Management Ltd acquired a new stake in shares of Cardiovascular Systems during the second quarter worth $204,000. Finally, Winslow Evans & Crocker Inc. increased its stake in shares of Cardiovascular Systems by 21.3% in the second quarter. Winslow Evans & Crocker Inc. now owns 6,550 shares of the medical device company’s stock worth $210,000 after buying an additional 1,150 shares during the last quarter. 75.34% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2017/09/17/cardiovascular-systems-inc-csii-given-consensus-recommendation-of-hold-by-analysts.html.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.